Curevac B.V. Stock Price, News & Analysis

CureVac (NASDAQ:CVAC), a pioneering mRNA-focused biotech company, announced the results of its Annual General Meeting. Shareholders approved all proposals, including key management changes. Axel Sven Malkomes was appointed to the Management Board, while Jean Stéphenne, Debra Barker, Craig A. Tooman, and Klaus Schollmeier were reappointed to the Supervisory Board. Mehdi Shahidi joined as a new Supervisory Board member. Additionally, KPMG Accountants N.V. was reappointed as external auditors for the financial year 2026.

CureVac (NASDAQ:CVAC) reported Q1 2025 financial results and business updates. The company received FDA clearance for CVHNLC, its lung cancer candidate, with clinical trials set to begin in H2 2025. Their glioblastoma study CVGBM completed enrollment in Q1 2025, with Phase 2 decision expected in H2 2025. The company maintains a strong cash position of €438.3 million, extending runway into 2028. Q1 2025 showed revenues of €0.9 million, down from €12.4 million in Q1 2024, and an operating loss of €54.7 million, improved from €73.3 million year-over-year. CureVac's core mRNA patents were upheld by the European Patent Office, with an infringement hearing against BioNTech/Pfizer scheduled for July 1, 2025. The company is also advancing its first urinary tract infection vaccine with U.S. IND filing planned for H2 2025.

CureVac (NASDAQ:CVAC) has secured another favorable ruling from the European Patent Office (EPO) in its ongoing patent litigation against BioNTech SE. The EPO largely dismissed opposition from BioNTech, Pfizer, and others, upholding CureVac's European patent EP 4 023 755 B1 with amended claims. This marks the second positive validity decision for CureVac, following a March 2025 ruling that upheld patent EP 3 708 668 B1. Both patents cover split poly-A tail technology, a foundational invention that enhances medical efficacy by improving protein expression in mRNA constructs. A hearing on the infringement of both patents is scheduled for July 1, 2025, at the Regional Court Düsseldorf. A favorable infringement decision would trigger damage assessment proceedings.

CureVac (NASDAQ:CVAC) reported its Q4 and full-year 2024 financial results, marking a year of strategic transformation. The company completed enrollment for Part B of its Phase 1 glioblastoma study, with data readout expected in H2 2025. The FDA cleared their sqNSCLC Phase 1 study to begin in H2 2025.

Key financial highlights include a strong cash position of €481.7 million as of December 31, 2024, with runway extended into 2028. Full-year 2024 revenues reached €535.2 million, including a €400 million upfront payment from GSK licensing agreement. The company reported an operating profit of €177.7 million for 2024.

Notable developments include a positive ruling from the European Patent Office confirming CureVac's patent validity in proceedings against BioNTech SE, with a U.S. jury trial postponed to September 2025. The company also received a €10 million milestone payment for initiating Phase 1 of a seasonal influenza/COVID-19 combination vaccine study with GSK.

CureVac (Nasdaq: CVAC), a global biotech company focused on developing mRNA-based transformative medicines, has scheduled its Fourth Quarter and Full-Year 2024 Financial Results announcement for April 10, 2025.

The company will host a conference call and webcast at 3 p.m. CET / 9 a.m. EST on the same day. Investors and interested parties can access the event through U.S. Toll-Free (+1-877-407-0989), International (+1-201-389-0921), and German landline (0800-182-0040) or cell phone (0800-184-4713) numbers.

Presentation slides will be available before the webcast through CureVac's website newsroom section, with a replay available afterward.

CureVac (Nasdaq: CVAC) has received FDA clearance for its Investigational New Drug (IND) application to begin a Phase 1 clinical trial of CVHNLC in squamous non-small cell lung cancer (sqNSCLC) patients. CVHNLC is an mRNA-based precision immunotherapy encoding eight tumor-associated antigens.

The trial will evaluate CVHNLC in combination with pembrolizumab, featuring two parts:

• Part A: dose-escalation study (100μg to 400μg) as first-line maintenance treatment
• Part B: optional dose expansion testing CVHNLC with first-line chemotherapy and pembrolizumab

Primary endpoints include dose-limiting toxicities and treatment-related adverse events, while secondary endpoints cover overall response rate, progression-free survival, and disease control rate. Patient treatment is expected to begin in the second half of 2025, with additional oncology candidates planned for clinical trials in 2026.

CureVac (NASDAQ:CVAC) has achieved a significant legal victory as the European Patent Office (EPO) largely dismissed BioNTech SE's opposition to CureVac's patent EP 3 708 668 B1, maintaining it in amended form. The patent covers CureVac's split poly-A tail technology, a foundational invention that enhances medical efficacy by improving protein expression in mRNA constructs.

This ruling marks a important milestone in the broader patent litigation between CureVac and BioNTech in Germany, which involves six intellectual property rights. An infringement hearing is scheduled for July 1, 2025, at the Regional Court Düsseldorf. If the court rules in CureVac's favor regarding infringement, it will trigger proceedings to assess damages.

CureVac (Nasdaq: CVAC) has been recognized as a Top 100 Global Innovator by LexisNexis® for the third consecutive year (2023-2025), highlighting its dynamic innovation and extensive intellectual property portfolio in mRNA technology. The recognition is based on the company's patent portfolio quality and advancement, evaluated through the Innovation Momentum methodology and Patent Asset Index.

As a pioneer in mRNA therapeutics, CureVac has developed proprietary foundational technologies over 25 years in mRNA design, delivery, and manufacturing. The company maintains one of the field's most comprehensive patent portfolios, with approximately 1,000 issued patents covering mRNA technology, manufacturing, and mRNA-based vaccines and therapies. These innovations have contributed significantly to COVID-19 vaccine development and other medical advances.

OKYO Pharma (NASDAQ: OKYO), a clinical-stage biopharmaceutical company focused on treating neuropathic corneal pain and inflammatory dry eye disease, announces its participation in the 4th Annual Virtual BTIG Ophthalmology Day on December 2nd, 2024. CEO Gary S. Jacob will engage in one-on-one meetings and lead a fireside chat from 2:40-3:15pm.

The event will feature over 20 medical technology and biotechnology companies, discussing latest developments in ophthalmic technologies and therapeutics. OKYO is developing treatments for NCP, which currently lacks FDA-approved therapies, and DED, representing a multi-billion-dollar market opportunity.